Category: III
-
CALQUENCE ® (acalabrutinib) plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. standard of care in patients with untreated mantle cell lymphoma in ECHO Phase III trial
•
First and only BTK inhibitor to demonstrate favorable overall survival trend vs. standard-of-care chemoimmunotherapy in this setting WILMINGTON, Del.–(BUSINESS WIRE)–Positive results from the ECHO Phase III trial showed AstraZeneca (NASDAQ:)’s CALQUENCE ® (acalabrutinib) in combination with bendamustine and rituximab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival…
-
China is ‘doubling down’ on chip investment with $47.5B Big Fund III
•
Beijing is “redoubling its efforts” in its quest to have China manufacture its own chips for billions more Investment round In the China Integrated Circuit Industry Investment Fund, known by its nickname “Big Fund”. The latest fund pledged as much money as the previous two rounds combined. Previous efforts to…
-
Teva schizophrenia drug Phase III results excite analysts
•
Teva Pharmaceutical Industries Limited (New York Stock Exchange: Tifa; level: Tifa) saw its share price rise by 12.8% yesterday, amid high trading volume, to its highest level in five years. The stock price of $15.74 gave it a market value of $17.8 billion, after the company reported first-quarter results with…